博雅生物：人凝血因子Ⅸ药物临床试验获批准

Core Viewpoint - The company, Boya Bio-Pharmaceutical (300294.SZ), has received approval from the National Medical Products Administration for a clinical trial of coagulation factor IX, aimed at treating patients with hemophilia B [1] Group 1 - The company has been granted a clinical trial approval notice for coagulation factor IX [1] - The clinical trial is intended for the treatment of bleeding in patients with coagulation factor IX deficiency (hemophilia B) [1]